Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.83 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.70 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.70 |
| ▸ | PFKP | Q01813 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.70 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.70 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392837 | 1.00 | MTOR (0.83) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449870 | 0.92 | MTOR (0.83) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL2905753 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL30324973 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL20734887 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22259415 | 0.90 | MTOR (0.85) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL18434209 | 0.90 | MTOR (0.85) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449769 | 0.90 | MTOR (0.84) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449843 | 0.87 | MTOR (0.73) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449848 | 0.87 | MTOR (0.79) | MTORPIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-07-05 | — | — | US | disclosed |
| WO-2020224585-A1 | SALT AND CRYSTAL FORM OF MTORC1/2 DUAL KINASE ACTIVITY INHIBITOR AND PREPARATION METHOD THEREFOR | 南京明德新药研发有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MEDSHINE DISCOVERY INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| EP-3712157-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | Medshine Discovery Inc. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| WO-2008023161-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MTOR, RICTOR, MAPKAP1 | MTOR 1/4885PIK3CA 26/4885PIK3CD 36/4885 |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MTOR, RICTOR, MAPKAP1 | MTOR 1/4885PIK3CA 26/4885PIK3CD 32/4885 |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 11/4885PIK3CD 40/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 11/4885PIK3CD 40/4885 |
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | MTOR 203/4885PIK3CA 1845/4885PIK3CD 2492/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | MTOR 24/4885PIK3CA 729/4885PIK3CD 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.